| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Global Pharmaceutical Product Research Division, Abbott Laboratories, Abbott Park, Illinois and 2 Ligand Pharmaceuticals Inc., San Diego, California
Requests for reprints: Stephen K. Tahir, Cancer Research, Global Pharmaceutical Product Research Division, Dept. 4N6, AP9, 100, Abbott Laboratories, Abbott Park Road, Abbott Park, IL 60064-6099. Phone: 847-938-3709; Fax: 847-938-1674; E-mail: stephen.k.tahir{at}abbott.com.
ABT-737 is a novel and potent Bcl-2 antagonist with single-agent activity against small-cell lung cancer (SCLC) cell lines. Here, we evaluated the contribution of Bcl-2 family members to the in vitro cellular response of several SCLC cell lines to ABT-737. Relatively higher levels of Bcl-2, Bcl-XL, Bim and Noxa, and lower levels of Mcl-1 characterized naïve SCLC cell lines that were sensitive to ABT-737. Conversely, a progressive decrease in the relative levels of Bcl-2 and Noxa and a progressive increase in Mcl-1 levels characterized the increased resistance of H146 cells following chronic exposure to ABT-737. Knockdown of Mcl-1 with small interfering RNA sensitized two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitized H196 cells to ABT-737. Combination treatment with DNA-damaging agents was extremely synergistic with ABT-737 and was associated with the down-regulation of Mcl-1 and the up-regulation of Noxa, Puma, and Bim in H196 cells. Thus, SCLC cells sensitive to ABT-737 expressed the target proteins Bcl-2 and Bcl-XL, whereas Mcl-1 and factors regulating Mcl-1 function seem to contribute to the overall resistance of SCLC cells to ABT-737. Overall, these observations provide further insight as to the mechanistic bases for ABT-737 efficacy in SCLC and will be helpful for profiling patients and aiding in the rational design of combination therapies. [Cancer Res 2007;67(3):1176–83]
This article has been cited by other articles:
|
|
 |
|
  S. Chen, Y. Dai, X.-Y. Pei, and S. Grant Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1 Mol. Cell. Biol., December 1, 2009; 29(23): 6149 - 6169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Kim, L. Moretti, L. R. Mitchell, D. K. Jung, and B. Lu Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non-Small Cell Lung Tumor Xenograft Model Clin. Cancer Res., October 1, 2009; 15(19): 6096 - 6105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bray, H.-Y. Chen, C. M. Karp, M. May, S. Ganesan, V. Karantza-Wadsworth, R. S. DiPaola, and E. White Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer Mol. Cancer Res., September 1, 2009; 7(9): 1487 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-M. Yang, D. Barbone, D. A. Fennell, and V. C. Broaddus Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular Spheroids Am. J. Respir. Cell Mol. Biol., July 1, 2009; 41(1): 14 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Li, Y. Zang, C. Li, N. S. Patel, J. R. Grandis, and D. E. Johnson ABT-737 Synergizes with Chemotherapy to Kill Head and Neck Squamous Cell Carcinoma Cells via a Noxa-Mediated Pathway Mol. Pharmacol., May 1, 2009; 75(5): 1231 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vogler, M. Butterworth, A. Majid, R. J. Walewska, X.-M. Sun, M. J. S. Dyer, and G. M. Cohen Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia Blood, April 30, 2009; 113(18): 4403 - 4413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hauck, B. H. Chao, J. Litz, and G. W. Krystal Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737 Mol. Cancer Ther., April 1, 2009; 8(4): 883 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Whitecross, A. E. Alsop, L. A. Cluse, A. Wiegmans, K.-M. Banks, C. Coomans, M. J. Peart, A. Newbold, R. K. Lindemann, and R. W. Johnstone Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors Blood, February 26, 2009; 113(9): 1982 - 1991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Kang and C. P. Reynolds Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy Clin. Cancer Res., February 15, 2009; 15(4): 1126 - 1132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Huang, K. Okumura, and F. A. Sinicrope BH3 Mimetic Obatoclax Enhances TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells Clin. Cancer Res., January 1, 2009; 15(1): 150 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Okumura, S. Huang, and F. A. Sinicrope Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737 Clin. Cancer Res., December 15, 2008; 14(24): 8132 - 8142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Mason, C. J. Vandenberg, C. L. Scott, A. H. Wei, S. Cory, D. C. S. Huang, and A. W. Roberts In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas PNAS, November 18, 2008; 105(46): 17961 - 17966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Micha, J. Cummings, A. Shoemaker, S. Elmore, K. Foster, M. Greaves, T. Ward, S. Rosenberg, C. Dive, and K. Simpson Circulating Biomarkers of Cell Death After Treatment with the BH-3 Mimetic ABT-737 in a Preclinical Model of Small-Cell Lung Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7304 - 7310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Song, K. Kandasamy, and A. S. Kraft ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis J. Biol. Chem., September 5, 2008; 283(36): 25003 - 25013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Shoemaker, M. J. Mitten, J. Adickes, S. Ackler, M. Refici, D. Ferguson, A. Oleksijew, J. M. O'Connor, B. Wang, D. J. Frost, et al. Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models Clin. Cancer Res., June 1, 2008; 14(11): 3268 - 3277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Konopleva, J. Watt, R. Contractor, T. Tsao, D. Harris, Z. Estrov, W. Bornmann, H. Kantarjian, J. Viallet, I. Samudio, et al. Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax) Cancer Res., May 1, 2008; 68(9): 3413 - 3420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tse, A. R. Shoemaker, J. Adickes, M. G. Anderson, J. Chen, S. Jin, E. F. Johnson, K. C. Marsh, M. J. Mitten, P. Nimmer, et al. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor Cancer Res., May 1, 2008; 68(9): 3421 - 3428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Kang, Z. Wan, Y. H. Kang, R. Sposto, and C. P. Reynolds Mechanism of Synergy of N-(4-Hydroxyphenyl)Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation J Natl Cancer Inst, April 16, 2008; 100(8): 580 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Hann, V. C. Daniel, E. A. Sugar, I. Dobromilskaya, S. C. Murphy, L. Cope, X. Lin, J. S. Hierman, D. L. Wilburn, D. N. Watkins, et al. Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer Cancer Res., April 1, 2008; 68(7): 2321 - 2328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Rudin, R. Salgia, X. Wang, L. D. Hodgson, G. A. Masters, M. Green, and E. E. Vokes Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103 J. Clin. Oncol., February 20, 2008; 26(6): 870 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Del Gaizo Moore, K. D. Schlis, S. E. Sallan, S. A. Armstrong, and A. Letai BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia Blood, February 15, 2008; 111(4): 2300 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Johnson, C. M. Rudin, and R. Salgia Novel and Targeted Agents for Small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): 363 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. De Biasio, J. A. Vrana, P. Zhou, L. Qian, C. K. Bieszczad, K. E. Braley, A. M. Domina, S. J. Weintraub, J. M. Neveu, W. S. Lane, et al. N-terminal Truncation of Antiapoptotic MCL1, but Not G2/M-induced Phosphorylation, Is Associated with Stabilization and Abundant Expression in Tumor Cells J. Biol. Chem., August 17, 2007; 282(33): 23919 - 23936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Dai and S. Grant Targeting Multiple Arms of the Apoptotic Regulatory Machinery Cancer Res., April 1, 2007; 67(7): 2908 - 2911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Olejniczak, C. Van Sant, M. G. Anderson, G. Wang, S. K. Tahir, G. Sauter, R. Lesniewski, and D. Semizarov Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains Mol. Cancer Res., April 1, 2007; 5(4): 331 - 339. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
